Avoid common mistakes on your manuscript.
To the Editor,
We read with great interest the article by Ye et al. [3] regarding tigecycline treatment for severe infection in children. In this cohort, only one patient with meningitis received tigecycline without clinical improvement. Management of extensively drug-resistant (XDR) Acinetobacter baumannii meningitis remains a therapeutic challenge in children due to the limited treatment options [1, 2]. Tigecycline, a glycylcycline with a broad spectrum of antibacterial activity, is not approved for children. But in the era of nosocomial infections due to multidrug-resistant bacteria, it can be a considerable option in life-threatening infections [1]. Here, we report two infants, who were diagnosed with ventriculoperitoneal shunt (VPS) meningitis due to XDR A. baumannii under colistin combination therapy. The addition of tigecycline to the treatment regimen of patients resulted in cure. Both A. baumannii isolates recovered from the cerebrospinal fluid (CSF) cultures of the patients showed susceptibility only to tigecycline (Table 1). Identification and antimicrobial susceptibility testing of A. baumannii were performed using the VITEK 2 automated system (bioMerieux, Marcy l’Etoile, France). Although tigecycline is not approved for central nervous system infections, it was the only available option for the treatment of our patients according to the antibiotic susceptibility results. CSF cultures became negative with normal clinical condition and laboratory values only after tigecycline was added to the treatment. Both of the patients had received antimicrobial treatment in different combinations before and during tigecycline treatment (Table 1). Additionally, the infected shunt was removed and an external ventricular drainage catheter was inserted in both patients. Clinical and laboratory features of the patients are summarized in Table 1.
In conclusion, tigecycline could be used as a salvage therapy, in combination with other antimicrobial agents, for children with VPS shunt meningitis caused by XDR A. baumannii when other therapies are not suitable.
Abbreviations
- CSF:
-
Cerebrospinal fluid
- EVD:
-
External ventricular drainage
- MIC:
-
Minimum inhibitory concentration
- XDR:
-
Extensively drug-resistant
- VPS:
-
Ventriculoperitoneal shunt
References
Mastrolia MV, Galli L, De Martino M, Chiappini E (2017) Use of tigecycline in pediatric clinical practice. Expert Rev Anti-Infect Ther 15:605–612
Michalopoulos A, Falagas ME (2010) Treatment of Acinetobacter infections. Expert Opin Pharmacother 11:779–788
Ye S, Zhang C, Lin S (2018) Preliminary experience with tigecycline treatment for severe infection in children. Eur J Pediatr 177:1489–1496
Author information
Authors and Affiliations
Contributions
MP: drafting of the manuscript and patient management; AOP: review of literature, critical revision, and approval of final draft of the manuscript
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Communicated by Nicole Ritz
Rights and permissions
About this article
Cite this article
Polat, M., Ozkaya-Parlakay, A. Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii. Eur J Pediatr 178, 117–118 (2019). https://doi.org/10.1007/s00431-018-3271-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-018-3271-2